- Page 2 and 3:
Experimental infection and protecti
- Page 4 and 5:
Experimental infection and protecti
- Page 6:
Contents Contents 5 Chapter 1 - Int
- Page 10 and 11:
Introduction 9 Malaria Malaria is o
- Page 12 and 13:
Introduction 11 Preclinical Clinica
- Page 14 and 15:
Introduction 13 pipeline of clinica
- Page 16 and 17:
Introduction 15 The division of ant
- Page 18 and 19:
Introduction 17 Figure 4. Populatio
- Page 20 and 21:
Introduction 19 candidates. Initial
- Page 22 and 23:
Introduction 21 - to identify param
- Page 24 and 25:
Introduction 23 20. Nussenzweig RS,
- Page 26 and 27:
Introduction 25 50. Ouedraogo AL, R
- Page 28:
Introduction 27 RTS,S/AS02 in malar
- Page 32 and 33:
Chapter 2 Safety and Immunogenicity
- Page 34 and 35:
Safety and Immunogenicity of a Reco
- Page 36 and 37:
Safety and Immunogenicity of a Reco
- Page 38 and 39:
Safety and Immunogenicity of a Reco
- Page 40 and 41:
Safety and Immunogenicity of a Reco
- Page 42 and 43:
Safety and Immunogenicity of a Reco
- Page 44 and 45:
Safety and Immunogenicity of a Reco
- Page 46 and 47: Safety and Immunogenicity of a Reco
- Page 48 and 49: Safety and Immunogenicity of a Reco
- Page 50 and 51: Safety and Immunogenicity of a Reco
- Page 52 and 53: Safety and Immunogenicity of a Reco
- Page 54 and 55: Safety and Immunogenicity of a Reco
- Page 56 and 57: Safety and Immunogenicity of a Reco
- Page 58 and 59: Chapter 3 Humoral immune responses
- Page 60 and 61: Humoral immune responses to a singl
- Page 62 and 63: Humoral immune responses to a singl
- Page 64 and 65: Humoral immune responses to a singl
- Page 66 and 67: Humoral immune responses to a singl
- Page 68 and 69: Humoral immune responses to a singl
- Page 70 and 71: Humoral immune responses to a singl
- Page 72 and 73: Humoral immune responses to a singl
- Page 74 and 75: Humoral immune responses to a singl
- Page 76 and 77: Humoral immune responses to a singl
- Page 78 and 79: Humoral immune responses to a singl
- Page 80: Humoral immune responses to a singl
- Page 83 and 84: Chapter 4 82 Abstract The functiona
- Page 85 and 86: 84 Chapter 4 Figure 1. Schematic re
- Page 87 and 88: 86 Chapter 4 Concentration (mg/ml,
- Page 89 and 90: 88 Chapter 4 Figure 4: Correlation
- Page 91 and 92: 90 Chapter 4 positively correlated
- Page 93 and 94: 92 Chapter 4 Acknowledgements The a
- Page 95: 94 Chapter 4 determinant of subsequ
- Page 99 and 100: Chapter 5 98 Abstract Exposing heal
- Page 101 and 102: 100 Chapter 5 Cohort RUNMC I RUNMC
- Page 103 and 104: 102 Chapter 5 fully engorged, i.e.
- Page 105 and 106: 104 Chapter 5 p-value* 0.44
- Page 107 and 108: 106 Chapter 5 Figure 1. Time to mic
- Page 109 and 110: 108 Chapter 5 Figure 3. Statistics
- Page 111 and 112: 110 Chapter 5 in time to microscopi
- Page 113 and 114: 112 Chapter 5 efficacy trials shows
- Page 115 and 116: 114 Chapter 5 References 1. McCall
- Page 117 and 118: 116 Chapter 5 30. Ponnudurai T, Len
- Page 119 and 120: Chapter 6 118 Abstract The developm
- Page 121 and 122: 120 Chapter 6 It is thus unclear wh
- Page 123 and 124: 122 Chapter 6 Figure 1. (A) Parasit
- Page 125 and 126: 124 Chapter 6 cycle gave a multipli
- Page 127 and 128: 126 Chapter 6 The community is in u
- Page 129 and 130: 128 Chapter 6 15. Dunachie SJ, Walt
- Page 131 and 132: 130 Chapter 7 Abstract The portfoli
- Page 133 and 134: 132 Chapter 7 serum at 5% haematocr
- Page 135 and 136: 134 Chapter 7 insectary of the Radb
- Page 137 and 138: 136 Chapter 7 NF135.C10 NF54 Re-sta
- Page 139 and 140: 138 Chapter 7 Figure 2. Parasite ki
- Page 141 and 142: 140 Chapter 7 parasitemia for NF135
- Page 143 and 144: 142 Chapter 7 Figure 4. Contributio
- Page 145 and 146: 144 Chapter 7 with either the NF54
- Page 147 and 148:
146 Chapter 7 Acknowledgements We t
- Page 149 and 150:
148 Chapter 7 14. Conway DJ, Machad
- Page 151 and 152:
150 Chapter 7 41. Douradinha B, Mot
- Page 153 and 154:
152 Chapter 8 Abstract Vaccines and
- Page 155 and 156:
154 Chapter 8 contaminated with bac
- Page 157 and 158:
156 Chapter 8 S1). The lot of PfSPZ
- Page 159 and 160:
158 Chapter 8 Figure 2. Parasite de
- Page 161 and 162:
160 Chapter 8 Adverse-event Number
- Page 163 and 164:
162 Chapter 8 inoculated the thawed
- Page 165 and 166:
164 Chapter 8 was safe and well tol
- Page 167 and 168:
166 Chapter 8 References 1. World M
- Page 169 and 170:
168 Chapter 8 28. Epstein JE, Tewar
- Page 171 and 172:
170 Chapter 8 Before Purification (
- Page 174 and 175:
Chapter 9 Protection against a Mala
- Page 176 and 177:
Protection against a Malaria Challe
- Page 178 and 179:
Protection against a Malaria Challe
- Page 180 and 181:
Protection against a Malaria Challe
- Page 182 and 183:
Protection against a Malaria Challe
- Page 184 and 185:
Protection against a Malaria Challe
- Page 186 and 187:
Protection against a Malaria Challe
- Page 188 and 189:
Protection against a Malaria Challe
- Page 190 and 191:
Protection against a Malaria Challe
- Page 192 and 193:
Protection against a Malaria Challe
- Page 194 and 195:
Chapter 10 Long-term protection aga
- Page 196 and 197:
Long-term protection against malari
- Page 198 and 199:
Long-term protection against malari
- Page 200 and 201:
Long-term protection against malari
- Page 202 and 203:
Long-term protection against malari
- Page 204 and 205:
Long-term protection against malari
- Page 206 and 207:
Long-term protection against malari
- Page 208 and 209:
Long-term protection against malari
- Page 210 and 211:
Long-term protection against malari
- Page 212 and 213:
Long-term protection against malari
- Page 214:
Long-term protection against malari
- Page 217 and 218:
216 Chapter 11 The development of a
- Page 219 and 220:
218 Chapter 11 antibodies induced b
- Page 221 and 222:
220 Chapter 11 the PfAMA1[25-545] F
- Page 223 and 224:
222 Chapter 11 growth in the blood,
- Page 225 and 226:
224 Chapter 11 Phase IIb field tria
- Page 227 and 228:
226 Chapter 11 were also tried at t
- Page 229 and 230:
228 Chapter 11 only ~45 infected mo
- Page 231 and 232:
230 Chapter 11 results in protectiv
- Page 233 and 234:
232 Chapter 11 immunoglobulins has
- Page 235 and 236:
234 Chapter 11 15. Lyke KE, Daou M,
- Page 237 and 238:
236 Chapter 11 42. Korsholm KS. One
- Page 239 and 240:
238 Chapter 11 72. Kester KE, McKin
- Page 241 and 242:
240 Chapter 11 101. Jin Y, Kebaier
- Page 243 and 244:
242 Chapter 11 132. House BL, Holli
- Page 246 and 247:
Summary, Samenvatting, List of publ
- Page 248:
Summary, Samenvatting, List of publ
- Page 251 and 252:
250 Chapter 12 nu wellicht moeten r
- Page 254 and 255:
Summary, Samenvatting, List of publ
- Page 256:
Summary, Samenvatting, List of publ
- Page 259 and 260:
258 Chapter 12 bijzonder dat je ook
- Page 261 and 262:
260 Chapter 12 hebben wij samen de
- Page 264:
Summary, Samenvatting, List of publ